Leukemia and Lymphoma Society: FDA Approval - Treatment Advance for Patients With Multiple Myeloma
December 19, 2020
December 19, 2020
WHITE PLAINS, New York, Dec. 19 -- The Leukemia and Lymphoma Society issued the following news release on Dec. 18:
The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio(R)) for adults with multiple myeloma who have had at least one prior type of treatment. Selinexor is used in combination with the chemotherapy drug bortezomib (Velcade(R)) and the corticosteroid dexamethasone in these patients.
LLS supported development of selinexor wi . . .
The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio(R)) for adults with multiple myeloma who have had at least one prior type of treatment. Selinexor is used in combination with the chemotherapy drug bortezomib (Velcade(R)) and the corticosteroid dexamethasone in these patients.
LLS supported development of selinexor wi . . .